AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$STAA

STAAR Surgical (STAA) Q3 2026 Earnings Call Transcript

STAAR Surgical (STAA) reported Q3 2026 revenue growth of 31% excluding prior-year adjustments, driven by EVO+ lens adoption in China and global market expansion. Gross margin was impacted by temporary factors but is expected to improve. The company announced a $50M share repurchase program and plans for new product trials. Asia Pacific, EMEA, and Americas regions showed varied growth, with China being the largest market.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 5:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 5:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
STAAR Surgical (STAA) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$STAABullishHigh
01

Why it matters

Earnings beat and buyback suggest near‑term upside, but reliance on higher ASPs may pose margin risk.

02

Market read

The earnings surprise and capital return initiative make STAAR a short‑term buying candidate.

03

What to watch

Supply constraints and inventory reductions could limit near‑term shipment growth despite demand.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

STAAR Surgical reported its Q3 2026 results, emphasizing growth in China, record profitability, and a new share repurchase program.

Company-level read

Ticker impact

$STAABullishHigh confidence
Context

Q3 2026 earnings call disclosed 31% revenue growth, record adjusted EBITDA and GAAP net income, and a $50M share repurchase authorization.

Expected impact

likely upward pressure as the market prices in better-than-expected revenue and profitability.

Evidence & confidence

Revenue and profit surprise, plus a new buyback program, typically drive short-term price gains.

Market effects

Sector

Positive outlook for the refractive surgery equipment sector, may lift peers focused on lens technology.

Regional

Strong China performance could boost sentiment for other medtech firms with exposure to Asian markets.

Global

Highlights a shift from laser to lens solutions, relevant for global eye‑care investors.

Counterpoint

What could challenge this read

If the revenue growth is driven by price hikes rather than volume, margins may compress later.

Key entities

  • Company
    STAAR Surgical

    US‑listed medtech firm specializing in implantable collamer lenses.

Read at source← All news

StorySTAAR Surgical posts strong Q3 2026 results and launches $50 M share buyback

Also covered by

2 outlets

Related articles

$STAAHigh

STAAR Surgical Reports Third Quarter 2026 Results

STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STAAR Surgical Reports Third Quarter 2026 Results Net Sales of $83.4 Million in the Third Quarter Net Income of $5.6 Million, with GAAP EPS of $0.11 Adjusted EBITDA [1] of $14.4 Million, or $0.28 per Diluted Share Record Revenue of $270.5 Million in the First Three Q

SEC EDGAR 8-K
$STAAMedAI 9/10

Overseas Investors, Local Philanthropy

SoftBank Group is in early talks to acquire Allied Universal for $30B ($18B equity, $12B debt). Allied, with $22.6B revenue, is a security firm with 800,000 employees. SoftBank's interest aligns with its AI and robotics ambitions, according to Reuters. Allied's CEO Steve Jones has focused on tech advances, including robotics. SoftBank's local investments include Sprint Corp. and Kingston Technology, with mixed outcomes.

ocbj.com
$STAAHigh

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

Staar Surgical (STAA) shares rose nearly 8% after Stifel's Thomas Stephan upgraded the stock to buy from hold, raising the price target to $31. He cited positive sales momentum, particularly in China, and potential for acquisitions. The company's FDA-approved products and lean operations were also highlighted.

aol.com
$STAAHigh

Why is STAAR Surgical stock surging today?

STAAR Surgical (STAA) stock rose 8.8% after Stifel upgraded it to Buy, raising its price target to $31. The firm cited a favorable product mix shift and easier comparisons, projecting 11% sales growth through 2028. The company also announced a $50M share buyback program, signaling confidence in its financial strength.

investing.com